Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Dex-loaded hyaluronic acid hydrogel microneedles significantly reduced pain in an acute inflammatory visceral pain model without sedation, suggesting a promising and patient-friendly alternative to intravenous delivery.

In this study, a single subcutaneous dose of PTH-CBD showed similar hair regrowth to daily oral ruxolitinib in mice with alopecia, possibly through increased beta-catenin and anagen transition stimulation.

This study found that the decision board is a reliable and valid tool for assessing treatment preferences in systemic lupus erythematosus patients, who tended to favor oral medication due to concerns about side effects.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

In this study of children with nephrotic syndrome treated with cyclophosphamide, 59.4% achieved remission, and 40.6% experienced side effects including nausea, vomiting, and hair loss.

This study found that metyrapone and etomidate provide dose-dependent anticonvulsant effects against seizures, with delayed effectiveness linked to increased neurosteroid levels.

This review found that Tolvaptan is the only drug shown to slow the progression of autosomal dominant polycystic kidney disease, but it does not affect mortality or kidney failure outcomes.

This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This case study reports that a woman with systemic lupus erythematosus experienced remission of her symptoms after receiving a combined therapy of corticosteroids and cytostatics.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

This study reports a unique case of coinheritance of BRCA2 and CYLD pathogenic variants in a man with metastatic malignant cylindroma, suggesting that recognizing such genetic profiles in rare conditions can provide new treatment options, including the potential use of therapies targeting BRCA deficiency.

This case report documents a 57-year-old man with nephrotic syndrome linked to recurrent chronic graft-versus-host disease and lupus-like symptoms, with improvement after cyclosporin and steroids; however, he died later from leukemia relapse.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This case study describes a 33-year-old woman with chronic myelogenous leukemia who developed nonscarring alopecia after starting nilotinib therapy, linked to perifollicular inflammation.

A woman with a specific mutation causing adrenal gland issues faced fertility problems, but careful hormone therapy helped her manage it successfully.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

In this open-label trial, 9-cis-retinoic acid showed moderate activity against Kaposi sarcoma in AIDS patients, but its use is limited by substantial side effects at higher doses.

This study found that both levetiracetam and valproate sodium effectively reduced seizure frequency and duration in patients with refractory epilepsy, but levetiracetam had fewer side effects related to liver enzyme changes.

This case report describes a patient with lamotrigine-associated drug-induced hypersensitivity syndrome requiring prolonged and complex treatment, with observed complications including extensive alopecia areata and autoimmune thyroiditis.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This article discusses the development of non-myeloablative stem cell transplants, which may expand the safe treatment range of allogeneic SCT, but presents no new clinical results.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study found that using methotrexate with corticosteroids may support hair regrowth in severe alopecia areata, but adverse effects and relapses were common, suggesting more controlled trials are needed.

In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.

In this case report, a 48-year-old woman with refractory discoid lupus erythematosus showed significant improvement, including hair regrowth, after treatment with deucravacitinib, suggesting its potential as an effective therapy for this condition.